Arcus Biosciences, Inc. (RCUS) News
Filter RCUS News Items
RCUS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RCUS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RCUS News From Around the Web
Below are the latest news stories about ARCUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RCUS as an investment opportunity.
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Arcus Biosciences Announces New Employment Inducement GrantsHAYWARD, Calif., December 24, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 66,900 shares of the Company’s common stock at an exercise price per share of $15.96, which was the closing price on December 23, 2024, |
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past weekIf you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long... |
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceHAYWARD, Calif., December 19, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Tuesday, January 14th, 2025, at 3:45pm PT. |
Arcus Biosciences to Participate in Two Upcoming Investor ConferencesHAYWARD, Calif., November 19, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: |
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter ReportArcus Biosciences, Inc. ( NYSE:RCUS ) defied analyst predictions to release its third-quarter results, which were ahead... |
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...Arcus Biosciences Inc (RCUS) reports robust financial health and strategic advancements in late-stage trials, despite facing competitive and strategic challenges. |
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue EstimatesArcus Biosciences (RCUS) delivered earnings and revenue surprises of 6.54% and 43.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline UpdateHAYWARD, Calif., November 06, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules — targeting TIGIT, HIF-2a, CD73, the A2a/A2b receptors, CD-39, AXL and PD-1 — across multiple common cancers. |
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung CancerHAYWARD, Calif., November 05, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, (DZ) versus zimberelimab (Z) or chemotherapy in patients with fro |